Prenetics Global Limited operates as a consumer health sciences company in the United States and Hong Kong. The company focuses on advancing human health and longevity through science-backed products under the IM8 brand. It also operates a consumer genetic testing brand in CircleDNA leveraging sequencing technology to …
| Periodo | 2026-11 | 2026-08 | 2026-06 | 2026-02 |
|---|---|---|---|---|
| Real | — | — | $-1.36 | $-0.19 |
| Estimado | $-1.00 | $-0.48 | $-0.77 | $-0.51 |
| Sorpresa | — | — | -76.6% | +62.7% |
| Métrica | PRE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 50.3% | 33.3% | +17.0% |
| Operating Margin | -157.2% | 3.2% | -160.5% |
| Net Margin | -151.2% | 1.6% | -152.8% |
| FCF Margin | -97.6% | 3.5% | -101.0% |
| ROE | -27.2% | 6.9% | -34.1% |
| ROA | -21.7% | 2.0% | -23.7% |
| Current Ratio | 2.36 | 1.35 | +1.01 |
| Debt / Equity | — | 0.41 | — |
| Tendencia (Piotroski) | FY24 | FY23 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -21.7% | — |
| ✗Flujo de caja operativo positivo | −$29M | −$14M |
| ✓Rentabilidad sobre activos al alza | -21.7% | -24.7% |
| ✓Caja operativa/activos supera al ROA | -13.5% | ROA -21.7% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 2.36 | 2.37 |
| ✗Sin aumentar el nº de acciones | 12M | 11M |
| ✓Margen bruto al alza | 50.3% | 40.6% |
| ✓Rotación de activos al alza | 0.14 | 0.09 |
| Calidad del negocio | FY24 |
|---|---|
| ✗Margen FCF > 10 % | -97.6% |
| ✗ROCE > 10 % | -27.2% |
| ✓Ventas > 5 %/año (3 años) | 34.7% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 39.0% |
Prenetics Global Ltd cotiza a 18.52 USD y tiene una capitalización bursátil de $361M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Consumo defensivo